Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Warner Chilcott Second Quarter Profit Soars on New Products

By Pharmaceutical Processing | August 6, 2010

Warner Chilcott PLC said today its second-quarter net income doubled as the Irish drug developer’s revenue soared from sales of newly acquired products.

The drugmaker said products acquired from Procter & Gamble Co. contributed $477.4 million toward revenue growth in the quarter. Warner Chilcott acquired P&G’s global branded prescription drug business for $3.1 billion last fall. The company gained a portfolio of products worth about $2.3 billion in annual revenue including blockbuster osteoporosis drug Actonel and Enablex, a treatment for overactive bladders.

In total, new products accounted for 63 percent of the company’s revenue.

The company said it earned $115.3 million, or 46 cents per share, in the three months that ended June 30. That compares with earnings of $56 million, or 22 cents per share, in the same quarter last year. Excluding certain one-time costs, adjusted earnings totaled 95 cents per share.

Revenue more than tripled to $815.6 million from $250.8 million. Sales of oral contraceptives rose 44 percent, and dermatology product sales were up 10 percent.

Analysts polled by Thomson Reuters expected, on average, earnings of 81 cents per share on $753 million in revenue.

Warner Chilcott said it booked a $9.4 million gain during the quarter from its distribution of inventories sold to LEO Pharma A/S and an $18.1 million reduction in the cost of sales tied to a contract termination. Meanwhile, selling and distribution expenses jumped to $116.4 million due in part to the products from P&G and expenses from a co-promotion agreement for Actonel with Sanofi-Aventis U.S. LLC.

Looking ahead, Warner Chilcott backed its prior outlook for 2010 adjusted profit of $3.45 to $3.55 per share. It has said revenue will be at the low end of its previously forecast range of $2.9 billion to $2.95 billion.

On average, analysts expect a profit of $3.37 per share and $2.99 billion in revenue, according to Thomson Reuters.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE